Introduction: Low-level chronic systematic inflammation is concurrently a predisposing factor and a consequence of both Chronic Obstructive Pulmonary Disease (COPD) and Metabolic Syndrome (MS). We hypothesize that these syndromes co-exist and overlap, as significant components of the comorbidome. In this meta-analysis we sought to assess the prevalence of MS among patients with COPD.Methods: Two independent investigators systematically reviewed the literature, to collect observational studies of patients with COPD (versus controls), who were assessed for the presence of metabolic syndrome. Heterogeneity and Risk of Bias were assessed, and data were combined using the fixed-effects model, since they were homogenous. Relative risk was adjusted for sex, age, BMI, smoking history, alcohol consumption and COPD severity.Results: Five studies, comprising a total population of 16,279 patients, were included in our meta-analysis. Data were found to be homogenous (Chi-squared= 2.72, p=0.605). No significant publication bias was found. MS was found to be significantly more prevalent among patients with COPD, with an Adjusted Relative Risk of 1.43 (95% Confidence Intervals: 1.213 to 1.681).Conclusion: Our meta-analysis suggests that MS is 43% more prevalent among patients with COPD, independently of the previously mentioned confounding factors. The prevalence of COPD among patients with MS will be assessed next.